Posted on

alamo cbd

In connection with the proposed transaction, the Company will file with the Securities and Exchange Commission (the “SEC”) and furnish to the Company’s stockholders a proxy statement and a shareholder vote will be required to close the transaction. Before making any voting decision, the Company’s stockholders are urged to read the proxy statement in its entirety when it becomes available and any other documents to be filed with the SEC in connection with the proposed acquisition or incorporated by reference in the proxy statement because they will contain important information about the proposed transaction and the parties to the proposed transaction.  Investors and shareholders may obtain a free copy of documents filed by Indoor Harvest Corp with the SEC at the SEC’s website at In addition, investors and shareholders may obtain a free copy of Indoor Harvest Corp’s filings with the SEC from Indoor Harvest Corp’s website at

On March 31, 2017, Alamo submitted an application under the Texas Compassionate Use Program (“TCUP”) to produce and dispense low-THC cannabis oils for the treatment of intractable epilepsy. Alamo has brought together prominent Texans from the United States military, Healthcare and Biopharmaceutical industries, as well as retired veterans of the Department of Public Safety (“DPS”), each committed to providing low-THC cannabis medicine to intractable epilepsy patients in Texas, while advancing the TCUP by collaborating with DPS officials. If licensed, Alamo would meet and exceed security, compliance, and quality standards set by regulators. The DPS is currently expected to notify those applicants that have been conditionally approved on April 30, 2017.

Indoor Harvest Corp, through its brand name Indoor Harvest ® , is a full service, state of the art design-build engineering firm for the indoor farming industry. Providing production platforms and complete custom-designed build-outs for both greenhouse and building integrated agriculture (BIA) grows, tailored to the specific needs of virtually any cultivar. Our patent pending aeroponic fixtures are based upon a modular concept in which primary components are interchangeable. Visit our website at for more information about our Company.

Consistent with the SEC’s April 2013 guidance on using social media outlets like Facebook and Twitter to make corporate disclosures and announce key information in compliance with Regulation FD, Indoor Harvest is alerting investors and other members of the general public that Indoor Harvest will provide weekly updates on operations and progress through its social media on Facebook and Twitter. Investors, potential investors and individuals interested in our company are encouraged to keep informed by following us on Twitter or Facebook. 

Pursuant to the Agreement, Indoor Harvest will sell, convey, transfer and assign to Alamo, twenty five million two hundred eighty thousand and twenty seven (25,280,027) shares of common stock of Indoor Harvest, par value Additionally, Vyripharm has entered into sponsored research agreements for its core platforms with the University of Texas Medical Branch Galveston, The University of Texas Health Science Center at Houston – Institute of Molecular Medicine Sponsored Research and The University of Texas M.D. Anderson Cancer Center. There is also an agreement with the National Institute of Drug Abuse and pending agreements with Baylor College of Medicine and the VA Hospital in Houston, TX..001, in the aggregate, in exchange for the transfer of such securities by the members of Alamo. Upon completion of the exchange, all of the Alamo interests shall be held by Indoor Harvest and Alamo shall become a wholly-owned subsidiary of Indoor Harvest.

Under the Joint Venture, Alamo will provide low-THC cannabis oil to Vyripharm using Indoor Harvest’s patent pending HPA platform in order to provide specific chemical expression profiles needed for Vyripharm’s research and patient treatments. The Joint Venture would allow the group to provide a unique ability in the industry, personalized patient medicine, by testing patient efficacy, utilizing the full entourage effect of cannabis, to those suffering from intractable epilepsy in the State of Texas. Vyripharm has extensive patent coverage on its imaging and delivery platforms and was recently granted patent allowance by the United States Patent and Trade Office for its comprehensive medical cannabis and hemp testing methodology platform [“Integrated Systems and Methods of Evaluating Cannabis and Cannabinoid Products for Public Safety, Quality Control and Quality Assurance Purposes,” Patent# US20150219610 A1].

HOUSTON, April 24, 2017 (GLOBE NEWSWIRE) — Indoor Harvest Corp (OTCQB:INQD) is pleased to announce, with Alamo CBD, LLC (“Alamo”), that on April 20, 2017 both Companies entered into a definitive share exchange agreement (the “Agreement”) to acquire 100% of the member ownership in Alamo.

Additionally, on March 23, 2017, Indoor Harvest and Alamo entered into a Contractual Joint Venture Agreement with Vyripharm Enterprises, LLC (“Vyripharm”), pursuant to which the parties agreed to participate in an unincorporated joint venture (the “Joint Venture”) to establish Alamo as a supplier of a variety of low-THC cannabis oil to Vyripharm for Vyripharm’s use in conducting research and development to create novel pharmaceutical and radiopharmaceutical compounds designed to image and treat intractable epilepsy.

HOUSTON, Jan. 03, 2017 (GLOBE NEWSWIRE) — Indoor Harvest Corp (OTCQB:INQD), through its brand name Indoor Harvest®, is a full service, state of the art design-build engineering firm for the indoor and vertical farming industry. The Company provides production platforms, mechanical systems and complete custom designed build outs for both greenhouse and building integrated agriculture grows.

The Company is pleased to announce it has entered into discussions to acquire 100% of the member interests in Alamo CBD, LLC. (“Alamo”), a Texas Limited Liability Company. Upon closing of the acquisition, it is intended that Indoor Harvest shareholders would retain 40% and Alamo shareholders would retain 60%, of the total issued and outstanding common stock of Indoor Harvest. It is contemplated that at or subsequent to the acquisition of Alamo by Indoor Harvest, Indoor Harvest will spin-off its vertical farming operations including its produce and engineering, procurement and construction related operations to Indoor Harvest shareholders at the closing of the acquisition. The Company’s remaining cannabis related assets, agreements, intellectual property and operations will remain with Indoor Harvest/Alamo. 

Chad Sykes, founder and Chief Innovation Officer of Indoor Harvest, added, “It will be the aspiration of our Company after acquisition of Alamo and thus becoming a joint venture partner with Vyripharm Biopharmaceuticals, to become a leader in the medical cannabinoids pharmaceutical space. Our aeroponic biomanufacturing platform allows for very precise control of plant expression, which allows a producer to create repeatable, consistent chemical profiles. We believe that unlike the small number of pharmaceutical groups operating in cannabis today, which use less precise cultivation methods and isolate certain chemical compounds, we can harness the benefits of the full entourage effect through the actual cultivation process. The planned Joint Venture that we’ll become part of our acquisition of Alamo has the potential to leverage our individual entities’ IP, agreements and relationships and would position us to become a major part of a serious player in the pharmaceutical space and medical cannabis research.”